Miodosky M, Cruset S, Beligoy LE, Freitas MJ, García-Lombardi M, Alfonso G, Cerutti A, Cordini G, De Stefano G, Gil M, Gómez S, Marull M, Zabaljauregui S, Agra M, Basso A, Beccacece M, Canosa V, Cugliari S, Devecchi C, Fragapane P, Funes ME, Gabriel A, Garate G, Giannini ME, Giordano L; Godoy MV, Golubizky V, Guanchiale L, Jarchum S, Mari LS, Márquez M, Nieto R, Noviello V, Plaza I, Premoli MS, Rodríguez A, Shanley C, Stemmelin G, Stivel M, Streitenberger D, Sturich AG, Ventriglia MV, Verón D, Viudez ML, Lis C, Rodger J, Hovsepian E, Bordone J

Idioma: Español
Referencias bibliográficas: 31
Paginas: 179-194
Archivo PDF: 432.74 Kb.

RESUMEN

Antecedentes: Brentuximab vedotin es una nueva opción terapéutica contra el linfoma de Hodgkin (LH) CD30+ y el linfoma anaplásico de células grandes sistémico.
Objetivo: Evaluar los criterios de respuesta y los eventos adversos a tres y seis meses del inicio del tratamiento con brentuximab vedotin en el linfoma de Hodgkin clásico y el linfoma anaplásico de células grandes sistémico en Argentina.
Material y Método: Análisis observacional, retrospectivo, multicéntrico dentro del Plan de Monitoreo de Eficacia y Seguridad Clínica de poscomercialización.
Resultados: Se incluyeron 89 pacientes con linfoma de Hodgkin clásico y 5 con linfoma anaplásico de células grandes sistémico con enfermedad en recaída o resistente. Se dispuso de datos de 71 (mediana: 3 ciclos de brentuximab vedotin, tasa de respuesta global: 78%, remisión completa: 37%) y 51 (mediana acumulativa: 6 ciclos de brentuximab vedotin, tasa de respuesta global: 74.5%, remisión completa: 45%) pacientes con linfoma de Hodgkin clásico a tres y seis meses, respectivamente. En general, el tratamiento con brentuximab vedotin fue bien tolerado.
Conclusiones: La administración de brentuximab vedotin puede generar respuestas favorables en pacientes con linfoma de Hodgkin clásico/linfoma anaplásico de células grandes sistémico con enfermedad en recaída o resistente y permitir que los sujetos con linfoma quimiorresistente accedan al trasplante autólogo de células progenitoras hematopoyéticas (TACPH) o al trasplante alogénico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/ dendritic cell neoplasms. Expert Rev Hematol 2017; 10 (3): 239‐249. doi: 10.1080/17474086.2017.1281122

2. Diefenbach CS, Connors JM, Friedberg JW, et al. Hodgkin lymphoma: Current status and clinical trial recommendations. JNCI J Natl Cancer Inst 2017; 109 (4): djw249. doi: 10.1093/jnci/djw249

3. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2018; 390 (10114): 2790-2802. doi: 10.1016/S0140-6736(17)32134-7

4. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002; 359: 2065-71. doi: 10.1016/S0140-6736(02)08938-9

5. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol 2005; 16: 625-633. doi: 10.1093/ annonc/mdi119

6. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102 (1): 53-9. doi: 10.1182/blood-2002-12-3842

7. Mehrzad V, Ashrafi F, Farrashi AR, et al. Comparison of ifosfamide, carboplatin and etoposide versus etoposide, steroid, and cytarabine cisplatin as salvage chemotherapy in patients with refractory or relapsed Hodgkin’s lymphoma. Adv Biomed Res 2017; 6: 30. DOI: 10.4103/2277- 9175.201687

8. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology 2008; 1: 326-33. doi: 10.1182/asheducation-2008.1.326

9. Kewalramani T, Nimer SD, Zelenetz AD, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin’s disease or aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplantation 2003; 32: 673-679. doi: 10.1038/ sj.bmt.1704214

10. Connors JM, Gerrie AS, Power MM, et al. Outcome of Hodgkin lymphoma after progression following autologous stem cell transplantation. Blood 2016; 128: 2994. https:// doi.org/10.1182/blood.V128.22.2994.2994

11. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127 (20): 2375-2390. https://doi. org/10.1182/blood-2016-01-643569

12. Sibon D, Fournier M, Brière J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte Trials. J Clin Oncol 2012; 30: 3939-3946. doi: 10.1200/JCO.2012.42.2345

13. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic largecell lymphoma is clinically and immunophenotypically different from both ALK_ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496-5504. doi: 10.1182/blood-2008-01-134270

14. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102: 1458-1465. doi: 10.1182/blood-2003-01-0039

15. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012; 30 (18): 2183-2189. doi: 10.1200/JCO.2011.38.0410

16. Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016; 128: 1562-1566. doi: 10.1182/blood-2016-02-699850

17. Gandolfi L, Pellegrini C, Casadei B, et al. Long-term responders after brentuximab vedotin: single-center experience on relapsed and refractory Hodgkin lymphoma and anaplastic large cell lymphoma patients. Oncologist 2016; 21 (12): 1436-1441. doi: 10.1634/theoncologist.2016-0112

18. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30: 2190-2196. doi: 10.1200/ JCO.2011.38.0402

19. Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2017; 130 (25): 2709-2717. doi: 10.1182/blood-2017-05-780049

20. Adcetris (brentuximab vedotin) package insert (Jan 13, 2012). 13 January 2012; http://www.accessdata.fda.gov/ drugsatfda_docs/label/2012/125388s0005lbl.pdf. Consultado el 1 de octubre de 2017.

21. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385 (9980): 1853-62. doi: 10.1016/ S0140-6736(15)60165-9

22. Disposición 8722. ANMAT. (21 de octubre de 2015) http://www.anmat.gov.ar/boletin_anmat/octubre_2015/ Dispo_8722-15.pdf. Consultada el 1 de octubre de 2017.

23. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 (5): 579-86. doi: 10.1200/JCO.2006.09.2403

24. Zinzani PL, Sasse S, Radford J y col. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. Crit Rev Oncol Hematol 2016; 104: 65-70. doi: 10.1016/j. critrevonc.2016.04.019

25. Angelopoulou MK, Vassilakopoulos TP, Batsis I, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. Hematol Oncol 2018; 36 (1): 174-181. doi: 10.1002/hon.2383

26. Salihoglu A, Elverdi T, Karadogan I, et al. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol 2015; 94: 415-420. doi: 10.1007/s00277-014-2215-9

27. Perrot A, Monjanel H, Bouabdallah R, et al. Impact of postbrentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica 2016; 101 (4): 466-73. doi: 10.3324/ haematol.2015.134213

28. Broccoli A, Pellegrini C, Di Rocco A, et al. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica 2017; 102 (11): 1931-1935. doi: 10.3324/haematol. 2017.171355

29. Carson KR, Newsome SD, Kim EJ, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 2014; 120 (16): 2464-71. doi: 10.1002/cncr.28712

30. Baxley AA, Kumm DE, Bishop CB, et al. Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation. J Oncol Pharm Pract 2013; 19 (3): 279-83. doi: 10.1177/1078155212464021

31. O’Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol 2018; 19 (2): 257-266. doi: 10.1016/S1470-2045(17)30912-9